# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $27 price target.
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical response...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Overweight rating ...
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.
Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023...
Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 sh...